AI Article Synopsis
- External innovation in the pharmaceutical sector is key for research and development, focusing on collaboration to boost innovation and reduce costs and risks, particularly in tackling neurodegenerative diseases.
- The Eisai-University College London (UCL) partnership serves as a case study, showcasing effective industry-academic collaboration for drug discovery.
- Over the first decade, seven projects were initiated, with the first – a new anti-tau antibody for Alzheimer’s disease – progressing to clinical trials, highlighting the success of this collaborative approach.
Article Abstract
External innovation initiatives in the pharmaceutical industry have become an integral part of research and development. Collaborations have been built to enhance innovation, mitigate risk, and share cost, especially for neurodegenerative diseases, a therapeutic area that has suffered from high attrition rates. This article outlines the Eisai-University College London (UCL) Drug Discovery and Development Collaboration as a case study of how to implement a productive industry-academic partnership. In the first 10 years, seven projects have been established and the first project, a novel anti-tau antibody for Alzheimer's disease, has entered clinical trials, providing early validation of this collaboration model.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.drudis.2023.103732 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!